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ABSTRACT: A recent Viewpoint article (Improving the plausibility of success with inefficient metrics. ACS Med. Chem. 
Lett. 2014, 5, 2-5) argued that the standard definition of ligand efficiency (LE) is mathematically invalid. In this viewpoint 
we address this criticism and show categorically that the definition of LE is mathematically valid. LE and other metrics 
such as lipophilic ligand efficiency (LLE) can be useful during the multi-parameter optimisation challenge faced by me-
dicinal chemists. 
The utility of some ligand efficiency (LE) metrics has re-
cently been challenged in a Viewpoint article in ACS Medici-
nal Chemistry Letters.
1
 This article also argued that earlier 
seminal work by Lipinski
2
 has been misinterpreted and has 
led to an over-simplistic application of cut offs for molecular 
properties such as MW < 500. The latter point is an interest-
ing topic for debate that has been discussed in detail many 
times, not least because it appeals to the iconoclastic nature 
of medicinal chemists. However the Viewpoint article also 
incorrectly states that LE and related metrics “violate the 
quotient rule of logarithms” and “appear plausible but are 
mathematical impossibilities”.  
The primary purpose of our Viewpoint article is to correct 
these mathematical statements and prevent them from prop-
agating through the literature. We also examine the behav-
iour of LE and lipophilic ligand efficiency (LLE) for two 
matched chemical pairs and compare this with a simple 
example of fuel efficiency.  Finally we briefly consider genu-
ine deficiencies of LE metrics so as to put valid criticism into 
perspective.  
LE is usually defined as the average free energy of binding 
in kcal/mol per non-hydrogen atom:
3,4 
LE =
(−2.303RT)
HAC
∙ log Kd 
where HAC denotes the heavy atom count (i.e., number of 
non-hydrogen atoms), R is the ideal gas constant and T is the 
temperature in Kelvin. At standard conditions of aqueous 
solution at 300K, neutral pH and remaining concentrations 
of 1M, -2.303RT approximates to -1.37 kcal/mol. Importantly, 
the equation converts Kd into an approximate free energy of 
binding meaning that ligand efficiency has units of 
(kcal/mol)/(heavy atom) (see note (a)).  
In reference 5, Shultz claims that “To be valid, LE must 
remain constant for each heavy atom that changes potency 
10-fold” and  “These metrics do not mathematically normal-
ize size or potency because they violate the quotient rule of 
logarithms. To obey this rule and be a valid mathematical 
function HAC would be subtracted from pIC50 and rendered 
independent of size and reference potency.” In other words, 
Shultz takes issue with LE as defined by Hopkins because he 
asserts that it violates the quotient rule of logarithms and is 
not a valid mathematical function (see note (b)).
 
However there is no requirement for LE to remain con-
stant for each additional heavy atom that increases potency 
by ten-fold. LE is simply an average and, like any other aver-
age, is not required to remain constant for each additional 
data point that differs by a fixed amount.  
The quotient rule of logarithms states that log(x/y) = 
log(x) – log(y). This relationship holds true for logarithms by 
definition. There is no general concept of a quotient rule of 
functions, so invoking the quotient rule of logarithms is not 
appropriate. LE is a simple and interpretable, mathematically 
well-defined function which divides a real number by an 
integer (see note (c)). It is perfectly valid mathematically to 
divide a real number by an integer. 
Another frequently used metric is Lipophilic Ligand Effi-
ciency (LLE or LipE) defined as:
6
  
LLE = pIC50 − cLogP 
We agree with Shultz that LLE is a useful and mathematical-
ly valid metric but we would also make the following com-
ment. It is essential to discriminate between views about the 
utility of efficiency metrics versus statements about their 
 mathematical validity. The former is a subject for debate that 
most medicinal chemists can engage in, whereas unfounded 
assertions about mathematical validity stifle debate and need 
to be made carefully and accurately. 
Ligand efficiency is a ratio of the free energy of binding to 
the size of the molecule. It is instructive to examine how one 
expects such a ratio to vary as changes are made to different-
ly sized molecules. Figure 1 gives an example of four Tanky-
rase inhibitors.
5
 The ring expansions of 1 to 2 (Change A) and 
of 3 to 4 (Change B) each cause an approximate ten-fold loss 
in affinity and a small (but similar) increase in lipophilicity. 
Change A and Change B give a similar reduction in LLE. In 
contrast, the reduction in LE is significantly larger for 
Change A than for Change B. Shultz argues that one would 
expect a composite parameter (i.e., LE) that normalises with 
respect to molecular size not to show size dependence of this 
kind.
5
 However we believe that this is the expected behaviour 
of any ratio. 
 
S N
NN
NH
O
N
O
O
S N
NN
NH
O
NN
NH
O
NS
NN
NH
O
N
O
O
NS
3
IC50= 0.630
pIC50= 6.2
cLogP = 1.8
LLE = 4.4
LE = 0.33
1
IC50= 0.103
pIC50= 7.0
cLogP = 1.3
LLE = 5.7
LE = 0.66
2
IC50= 0.980
pIC50= 6.0
cLogP = 1.4
LLE = 4.6
LE = 0.53
4
IC50= 4.71
pIC50= 5.3
cLogP = 2.0
LLE = 3.3
LE = 0.28
Change A
Change B
 
Figure 1. Tankyrase inhibitors where the same single atom 
addition (i.e, ring expansion) has been performed on mole-
cules 1 and 3 that are of different size. Structures and data 
(including LE and LLE/LipE values) are taken from reference 
5. IC50 is given in M and LE is given in (kcal/mol)/(heavy 
atom).  
 
Figure 2 gives the familiar example of fuel efficiency, FE. 
Car journeys 1 and 3 have good FE associated with driving on 
the highway. Addition of the extra stage of town-driving 
causes a drop in FE for both journeys 2 and 4 but the drop in 
FE is largest for journey 2, the shorter one. The analogy with 
Figure 1 is clear – the same change to molecules 1 and 3 re-
duces potency in both cases, but has more effect on the over-
all LE of the smaller molecule 2, than it does on the larger 
molecule 4.  
The higher sensitivity of LE for small molecules is a direct 
result of the functional form of LE and this behaviour is 
shared by similar functions such as the fuel efficiency of car 
journeys. At very low numbers of heavy atoms there is the 
potential for potent molecules to have very large LE but as a 
practical matter, medicinal chemists have little interest in 
extremely small fragments (e.g., molecular weight < 75 Da). 
The behaviour of LE as HAC tends towards zero is directly 
analogous to the behaviour of fuel efficiency as the amount 
of fuel used in a journey tends towards zero. We agree that it 
is important that medicinal chemists are aware of this behav-
iour but do not agree that this negates the usefulness of LE. 
 
 
Figure 2. The effect on overall Fuel Efficiency (FE) of add-
ing the same inefficient stage of 100 miles in town traffic to 
two fuel efficient journeys of different length. 
 
LE shows the expected behaviour for a ratio of variables. 
We believe that it can be a very useful metric but its simple 
and interpretable functional form ((kcal/mol)/(heavy atom)) 
means that it has deficiencies as well as strengths. 
First, all non-hydrogen atoms are counted the same, so the 
introduction of a CH3, NH2, OH, F, Cl or Br will cause the 
same change in HAC; no account is taken of the advantages 
and disadvantages of introducing polarity or charged species 
into a molecule. This highlights the risk of using LE in isola-
tion without also considering other properties such as poten-
cy, cLogP, LLE, solubility, pharmacokinetics, etc. 
More interestingly it has been observed across large num-
bers of compounds that the optimal or average LE is system-
atically higher for small ligands than for large ligands.
4,7
 This 
is a consequence of protein binding sites being limited in 
their size. Additionally the quality of fit inevitably degrades 
as the ligand gets larger because it becomes increasingly 
difficult to form optimal interactions with every site on the 
protein without introducing unfavourable ligand strain. Size-
corrected and mathematically-valid adjustments to LE, such 
as FQ
7 
and SILE
8
, have been proposed. We have found both 
LE and its size-corrected versions to be useful when compar-
ing molecules of different sizes and potencies, and for track-
ing progress during the optimisation of hits into leads. It 
should be noted that at constant LE, potency is directly pro-
portional to heavy atom count – hence striving to maintain 
LE during optimisation, when size often increases, can be a 
worthwhile tactic.
9
 
The role of LE is to help control the molecular size of a se-
ries during optimisation or to help decide whether one series 
is more suitable for progression than another. LE values vary 
for different targets;
9
 low LE values are expected for protein-
protein interaction (PPI) targets and higher values are ex-
 pected for more tractable targets such as kinases. In particu-
lar, LE will be less useful for highly tractable targets where 
obtaining small potent compounds is comparatively straight-
forward and where optimisation will naturally focus on other 
properties (e.g., in vivo properties). The PARPs (such as 
tankyrase) are good examples of targets where obtaining 
high LE values is less challenging because a number of very 
small molecules have high potencies for their size (e.g., 3-
methoxybenzamide has a potency of between 1 and 10 M 
versus various PARPs). 
Lipophilicity is an extremely important quantity to control 
during optimisation and Shultz rightly extols the virtues of 
LLE. LLE explicitly considers the balance of lipophilicity with 
potency and can be very useful in comparing HTS hits or 
during lead optimisation. However despite its strengths, it 
can be difficult to use LLE in comparing molecules of very 
different sizes and potencies.  Also LLE will be less useful 
where the target requires very polar molecules. An example 
of this would be influenza neuraminidase where the first 
drug, zanamivir (cLogP = -5.6) was too polar for oral admin-
istration and the introduction of extra lipophilicity in osel-
tamivir (cLogP = 2.1) led to a more successful, orally bioavail-
able drug. LLE is a less important parameter for neuramini-
dase because, in contrast to most targets, producing potent 
molecules with low lipophilicity is not a major challenge.  
We believe that obtaining a lead series with the right bal-
ance of potency, cLogP and molecular size is a challenge for 
many biological targets and we have previously observed 
that, for such challenging targets, drugs often have optimal 
combinations of LE and LLE values.
9
 Obtaining good in vivo 
properties is often facilitated by having the correct balance of 
potency and physical properties but this is not a guarantee of 
success. We agree with Shultz about the inherent difficulties 
of multi-parameter lead optimisation and we also agree that 
there is no one metric that correlates with success. However 
we believe there are many biological targets where a consid-
eration of efficiency metrics is helpful to the decision-making 
process. 
The recent Viewpoint article by Shultz summarizes a 
number of provocative opinions, many of which are interest-
ing topics for debate and some of which we agree with. It is 
certainly true that many drugs are larger than 500Da and 
that many drugs have high cLogP and poor solubility. Our 
belief is that compounds of this type are generally more 
difficult to optimise into candidates, take longer to develop, 
and have more chance of suffering attrition in clinical trials. 
A critical and balanced examination of the evidence support-
ing this belief is a welcome subject for debate. It is also inter-
esting and important to question whether medicinal chem-
ists have been over-zealous in their adherence to physical 
property guidelines. 
However the tone of the Viewpoint is sometimes unhelpful 
to effective debate, and more importantly contains serious 
inaccuracies which hinder scientific inquiry. One can discuss 
the merits of LE and other metrics such as LLE, LELP, LLEAT 
and FQ,
10,11
 but they are all mathematically valid. The func-
tional form of LE gives the entirely expected behaviour for a 
ratio of variables in that the LE of smaller molecules is more 
sensitive to changes than the LE of larger molecules. 
Medicinal chemists are routinely faced with a highly chal-
lenging multi-parameter optimisation problem and an in-
complete set of data to guide them to acceptable solutions. 
Heuristics such as LE are tools to help navigate the design 
space but they are not intended to replace detailed consider-
ation of the many in vitro and in vivo properties required in a 
successful drug. Our experience is that efficiency metrics can 
be useful to help the drug discovery process and so we en-
courage medicinal chemists to explore them on their own 
projects.  
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(a) The units arise directly from the conversion of an equilib-
rium constant (often approximated by the IC50) into a free 
energy of binding using one of the fundamental laws of 
chemistry (∆G =  −RT ln K). 
(b) It is interesting to question if a number of fundamental 
physical equations, such as the Nernst equation, satisfy the 
criteria given in reference 5. 
(c) LE is a mathematically well-defined function 𝑓: ℝ+ × ℕ →
ℝ+ that maps the Cartesian product space domain of positive 
reals and positive integers to the codomain of positive reals. 
For a definition of a function, see Haaser, N.B.; Sullivan, J.A. 
Real Analysis; Dover, 1991. 
(d) Views expressed in this editorial are those of the authors 
and not necessarily the views of the ACS. 
(e) The authors declare no competing financial interests. 
LE, ligand efficiency; MW, molecular weight; LLE, lipophilic 
ligand efficiency (also called LipE, lipophilic efficiency); 
HAC, heavy atom count; FE, fuel efficiency; FQ, fit quality; 
SILE, size independent LE; PARP, poly ADP ribose polymer-
ase; HTS, high throughput screening; LELP, lipophilicity 
corrected LE; LLEAT, Astex LLE.  
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